EK, Eastman Kodak Co.
** EK, in response to rumors circulating in the capital markets, reported that it is committed to meeting all of its obligations and has no intention of filing for bankruptcy.
EK helps consumers, businesses, and creative professionals unleash the power of images, information, and printing to enrich their lives.
More about EK at www.kodak.com
ENMD, EntreMed Inc.
** ENMD reported its Phase 2 study of ENMD-2076 demonstrated promising activity in platinum-resistant ovarian cancer patients.
ENMD-2076 is an orally-active, Aurora A/angiogenic kinase inhibitor with a unique kinase selectivity profile and multiple mechanisms of action. ENMD-2076 has been shown to inhibit a distinct profile of angiogenic tyrosine kinase targets in addition to the Aurora A kinase. Aurora kinases are key regulators of mitosis (cell division), and are often over-expressed in human cancers.
ENMD is a clinical-stage pharmaceutical company committed to developing ENMD-2076, a selective angiogenic kinase inhibitor, for the treatment of cancer.
More about ENMD at www.entremed.com
EBS, Emergent BioSolutions, Inc.
** EBS has received an award to supply the U.S. government with 44.75 million doses of BioThrax (Anthrax Vaccine Adsorbed) over a period of five years for a total value of up to $1.25 billion.
BioThrax is the only vaccine licensed by the FDA to protect against anthrax infection.
Initial deliveries under this award are expected to commence in 2011 with 8.5 million doses scheduled to be delivered during the first contract year. Deliveries are scheduled to continue, subject to availability of funding, through September 2016.
EBS protects and enhances life by developing and manufacturing vaccines and therapeutics that are supplied to healthcare providers and purchasers for use in preventing and treating disease.
More about EBS at www.emergentbiosolutions.com.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyOmega.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyOmega.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://pennyomega.com/disclaimer). Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a media-advertisement and newswire company. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.